How to buy Sangamo Therapeutics stock - 11 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sangamo Therapeutics stock

Own Sangamo Therapeutics stock in just a few minutes.

Sangamo Therapeutics, Inc is a biotechnology business based in the US. Sangamo Therapeutics shares (SGMO) are listed on the NASDAQ and all prices are listed in US Dollars. Sangamo Therapeutics employs 413 staff and has a trailing 12-month revenue of around USD$118.2 million.

How to buy shares in Sangamo Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Sangamo Therapeutics. Find the stock by name or ticker symbol: SGMO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sangamo Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Sangamo Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Sangamo Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Sangamo Therapeutics share price

Use our graph to track the performance of SGMO stocks over time.

Sangamo Therapeutics shares at a glance

Information last updated 2021-04-09.
52-week rangeUSD$6.97 - USD$19.43
50-day moving average USD$11.9776
200-day moving average USD$12.4047
Wall St. target priceUSD$19.8
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.988

Buy Sangamo Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sangamo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sangamo Therapeutics financials

Revenue TTM USD$118.2 million
Gross profit TTM USD$-62,455,000
Return on assets TTM -10.27%
Return on equity TTM -26.05%
Profit margin -102.37%
Book value $3.507
Market capitalisation USD$1.6 billion

TTM: trailing 12 months

Shorting Sangamo Therapeutics shares

There are currently 16.6 million Sangamo Therapeutics shares held short by investors – that's known as Sangamo Therapeutics's "short interest". This figure is 6.1% up from 15.6 million last month.

There are a few different ways that this level of interest in shorting Sangamo Therapeutics shares can be evaluated.

Sangamo Therapeutics's "short interest ratio" (SIR)

Sangamo Therapeutics's "short interest ratio" (SIR) is the quantity of Sangamo Therapeutics shares currently shorted divided by the average quantity of Sangamo Therapeutics shares traded daily (recently around 1.5 million). Sangamo Therapeutics's SIR currently stands at 11.26. In other words for every 100,000 Sangamo Therapeutics shares traded daily on the market, roughly 11260 shares are currently held short.

However Sangamo Therapeutics's short interest can also be evaluated against the total number of Sangamo Therapeutics shares, or, against the total number of tradable Sangamo Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sangamo Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Sangamo Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.1157% of the tradable shares (for every 100,000 tradable Sangamo Therapeutics shares, roughly 116 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Sangamo Therapeutics.

Find out more about how you can short Sangamo Therapeutics stock.

Sangamo Therapeutics share dividends

We're not expecting Sangamo Therapeutics to pay a dividend over the next 12 months.

Sangamo Therapeutics share price volatility

Over the last 12 months, Sangamo Therapeutics's shares have ranged in value from as little as $6.97 up to $19.43. A popular way to gauge a stock's volatility is its "beta".

SGMO.US volatility(beta: 1.78)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sangamo Therapeutics's is 1.7843. This would suggest that Sangamo Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Sangamo Therapeutics overview

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site